Crispr Therapeutics AG (NASDAQ: CRSP) insider transactions
In the twelve months to 10 November 2026, executives and directors of Crispr Therapeutics AG reported 30 open-market sales of 327,421 shares ($17.9m) and 0 open-market purchases, by 6 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 19 October 2026 | Kulkarni Samarth | Chief Executive Officer | Open-market sale | −47,837 | $49.78 | 311,899 | Form 4 |
| 16 October 2026 | Kulkarni Samarth | Chief Executive Officer | Option exercise | +100,000 | — | 359,736 | Form 4 |
| 14 October 2026 | George Simeon | Director | Option exercise, 10b5-1 plan | +30,000 | $14.00 | 30,000 | Form 4 |
| 14 October 2026 | George Simeon | Director | Open-market sale, 10b5-1 plan | −14,514 | $49.63 | 15,486 | Form 4 |
| 14 October 2026 | Kulkarni Samarth | Chief Executive Officer | Open-market sale | −4,098 | $49.26 | 259,736 | Form 4 |
| 14 October 2026 | Kasinger James R. | General Counsel and Secretary | Open-market sale | −1,040 | $49.26 | 95,857 | Form 4 |
| 13 October 2026 | Kulkarni Samarth | Chief Executive Officer | Option exercise | +8,333 | — | 263,834 | Form 4 |
| 13 October 2026 | Kasinger James R. | General Counsel and Secretary | Option exercise | +2,113 | — | 96,897 | Form 4 |
| 6 October 2026 | Kasinger James R. | General Counsel and Secretary | Option exercise, 10b5-1 plan | +1,990 | $13.62 | 96,774 | Form 4 |
| 6 October 2026 | Kasinger James R. | General Counsel and Secretary | Open-market sale, 10b5-1 plan | −1,990 | $60.04 | 94,784 | Form 4 |
| 22 September 2026 | Kasinger James R. | General Counsel and Secretary | Option exercise, 10b5-1 plan | +10,400 | $13.62 | 105,184 | Form 4 |
| 22 September 2026 | Kasinger James R. | General Counsel and Secretary | Open-market sale, 10b5-1 plan | −10,400 | $60.24 | 94,784 | Form 4 |
| 17 September 2026 | Behbahani Ali | Director | Option exercise | +30,000 | $14.00 | 30,316 | Form 4 |
| 17 September 2026 | Behbahani Ali | Director | Open-market sale | −13,679 | $57.09 | 16,637 | Form 4 |
| 7 August 2026 | Prasad Raju | Chief Financial Officer | Gift | −750 | — | 14,815 | Form 4 |
| 29 May 2026 | Patel Naimish | Chief Medical Officer | Open-market sale | −3,786 | $55.62 | 19,357 | Form 4 |
| 28 May 2026 | Patel Naimish | Chief Medical Officer | Option exercise | +10,000 | — | 23,143 | Form 4 |
| 23 March 2026 | Prasad Raju | Chief Financial Officer | Open-market sale | −3,708 | $46.78 | 15,565 | Form 4 |
| 23 March 2026 | Kulkarni Samarth | Chief Executive Officer | Open-market sale | −10,020 | $46.78 | 255,501 | Form 4 |
| 23 March 2026 | Kasinger James R. | General Counsel and Secretary | Open-market sale | −3,182 | $46.78 | 94,308 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Crispr Therapeutics AG page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.